Cargando…

Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013

PURPOSE: The Continuing to Confront COPD International Patient Survey aimed to estimate the prevalence and burden of COPD globally and to update findings from the Confronting COPD International Survey conducted in 1999–2000. MATERIALS AND METHODS: Chronic obstructive pulmonary disease (COPD) patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Landis, Sarah H, Muellerova, Hana, Mannino, David M, Menezes, Ana M, Han, MeiLan K, van der Molen, Thys, Ichinose, Masakazu, Aisanov, Zaurbek, Oh, Yeon-Mok, Davis, Kourtney J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057333/
https://www.ncbi.nlm.nih.gov/pubmed/24944511
http://dx.doi.org/10.2147/COPD.S61854
_version_ 1782320943932112896
author Landis, Sarah H
Muellerova, Hana
Mannino, David M
Menezes, Ana M
Han, MeiLan K
van der Molen, Thys
Ichinose, Masakazu
Aisanov, Zaurbek
Oh, Yeon-Mok
Davis, Kourtney J
author_facet Landis, Sarah H
Muellerova, Hana
Mannino, David M
Menezes, Ana M
Han, MeiLan K
van der Molen, Thys
Ichinose, Masakazu
Aisanov, Zaurbek
Oh, Yeon-Mok
Davis, Kourtney J
author_sort Landis, Sarah H
collection PubMed
description PURPOSE: The Continuing to Confront COPD International Patient Survey aimed to estimate the prevalence and burden of COPD globally and to update findings from the Confronting COPD International Survey conducted in 1999–2000. MATERIALS AND METHODS: Chronic obstructive pulmonary disease (COPD) patients in 12 countries worldwide were identified through systematic screening of population samples. Telephone and face-to-face interviews were conducted between November 2012 and May 2013 using a structured survey that incorporated validated patient-reported outcome instruments. Eligible patients were adults aged 40 years and older who were taking regular respiratory medications or suffered with chronic respiratory symptoms and reported either 1) a physician diagnosis of COPD/emphysema, 2) a physician diagnosis of chronic bronchitis, or 3) a symptom-based definition of chronic bronchitis. The burden of COPD was measured with the COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) Dyspnea Scale. RESULTS: Of 106,876 households with at least one person aged ≥40 years, 4,343 respondents fulfilled the case definition of COPD and completed the full survey. COPD prevalence ranged from 7% to 12%, with most countries falling within the range of 7%–9%. In all countries, prevalence increased with age, and in all countries except the US was greater among men (range 6%–14%) than among women (range 5%–11%). A significant disease burden was observed when considering COPD symptoms or health status, and showed wide variations across countries. Prevalence of moderate-to-severe dyspnea (mMRC scale ≥2) ranged from 27% to 61%, and mean CAT score ranged from 16.0 to 24.8, indicating medium-to-high impairment. CONCLUSION: This survey, representing 12 countries, showed similar rates of estimated COPD prevalence across countries that were higher than those reported a decade ago in the original Confronting COPD International Survey. A significant burden of COPD was demonstrated by symptoms and health care-resource use, similar to that reported in the original survey.
format Online
Article
Text
id pubmed-4057333
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40573332014-06-18 Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 Landis, Sarah H Muellerova, Hana Mannino, David M Menezes, Ana M Han, MeiLan K van der Molen, Thys Ichinose, Masakazu Aisanov, Zaurbek Oh, Yeon-Mok Davis, Kourtney J Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: The Continuing to Confront COPD International Patient Survey aimed to estimate the prevalence and burden of COPD globally and to update findings from the Confronting COPD International Survey conducted in 1999–2000. MATERIALS AND METHODS: Chronic obstructive pulmonary disease (COPD) patients in 12 countries worldwide were identified through systematic screening of population samples. Telephone and face-to-face interviews were conducted between November 2012 and May 2013 using a structured survey that incorporated validated patient-reported outcome instruments. Eligible patients were adults aged 40 years and older who were taking regular respiratory medications or suffered with chronic respiratory symptoms and reported either 1) a physician diagnosis of COPD/emphysema, 2) a physician diagnosis of chronic bronchitis, or 3) a symptom-based definition of chronic bronchitis. The burden of COPD was measured with the COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) Dyspnea Scale. RESULTS: Of 106,876 households with at least one person aged ≥40 years, 4,343 respondents fulfilled the case definition of COPD and completed the full survey. COPD prevalence ranged from 7% to 12%, with most countries falling within the range of 7%–9%. In all countries, prevalence increased with age, and in all countries except the US was greater among men (range 6%–14%) than among women (range 5%–11%). A significant disease burden was observed when considering COPD symptoms or health status, and showed wide variations across countries. Prevalence of moderate-to-severe dyspnea (mMRC scale ≥2) ranged from 27% to 61%, and mean CAT score ranged from 16.0 to 24.8, indicating medium-to-high impairment. CONCLUSION: This survey, representing 12 countries, showed similar rates of estimated COPD prevalence across countries that were higher than those reported a decade ago in the original Confronting COPD International Survey. A significant burden of COPD was demonstrated by symptoms and health care-resource use, similar to that reported in the original survey. Dove Medical Press 2014-06-06 /pmc/articles/PMC4057333/ /pubmed/24944511 http://dx.doi.org/10.2147/COPD.S61854 Text en © 2014 Landis et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Landis, Sarah H
Muellerova, Hana
Mannino, David M
Menezes, Ana M
Han, MeiLan K
van der Molen, Thys
Ichinose, Masakazu
Aisanov, Zaurbek
Oh, Yeon-Mok
Davis, Kourtney J
Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013
title Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013
title_full Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013
title_fullStr Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013
title_full_unstemmed Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013
title_short Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013
title_sort continuing to confront copd international patient survey: methods, copd prevalence, and disease burden in 2012–2013
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057333/
https://www.ncbi.nlm.nih.gov/pubmed/24944511
http://dx.doi.org/10.2147/COPD.S61854
work_keys_str_mv AT landissarahh continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013
AT muellerovahana continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013
AT manninodavidm continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013
AT menezesanam continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013
AT hanmeilank continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013
AT vandermolenthys continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013
AT ichinosemasakazu continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013
AT aisanovzaurbek continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013
AT ohyeonmok continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013
AT daviskourtneyj continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013